Switch effects from daily to intermittent treatment with a daily regimen dosage for Mycobacterium avium complex pulmonary disease

M. Matsumoto (Ono, Japan), K. Masuda (Ono, Japan), K. Kaneshiro (Ono, Japan), K. Takatsuki (Ono, Japan)

Source: International Congress 2019 – Clinical and translational studies of bronchiectasis and non-TB mycobacterial infection
Disease area: Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Matsumoto (Ono, Japan), K. Masuda (Ono, Japan), K. Kaneshiro (Ono, Japan), K. Takatsuki (Ono, Japan). Switch effects from daily to intermittent treatment with a daily regimen dosage for Mycobacterium avium complex pulmonary disease. 2156

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Treatment of severe Mycobacterium avium complex pulmonary disease with a adjunctive amikacin and clofazimine versus standard regimen alone, a retrospective study
Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection I
Year: 2019




Effect of clarithromycin alone and clarithromycin containing regimen for mycobacteriun avium complex pulmonary disease
Source: Eur Respir J 2006; 28: Suppl. 50, 558s
Year: 2006

Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease
Source: Eur Respir J, 54 (1) 1900118; 10.1183/13993003.00118-2019
Year: 2019



The effect of combined chemotherapy according to the guidelines on the treatment for Mycobacterium avium complex pulmonary disease
Source: Eur Respir J 2002; 20: Suppl. 38, 546s
Year: 2002

Long-term observation of pulmonary Mycobacterium avium complex disease treated with chemotherapy following the guidelines for treatment
Source: Annual Congress 2009 - Extrapulmonary tuberculosis and non-tuberculous-mycobacteria (NTM) infections
Year: 2009


Comparison of safety and efficacy between clarithromycin- and azithromycin-containing regimens in Mycobacterium avium complex lung disease
Source: International Congress 2019 – Complex respiratory infections in clinical practice
Year: 2019

Association between injectable aminoglycoside treatment duration and outcomes in cavitary Mycobacterium avium complex lung disease
Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria
Year: 2018



Clinical efficacy and safety of fluoroquinolone containing regimens in patients with Mycobacterium avium complex pulmonary disease
Source: Eur Respir J, 55 (4) 1901240; 10.1183/13993003.01240-2019
Year: 2020



Treatment of refractory mycobacterium avium complex lung disease with a moxifloxacin-containing regimen
Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Year: 2013

Paradoxical response during antibiotic treatment in patients with Mycobacterium avium complex lung disease
Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis
Year: 2020


The clinical effect of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease - including a long-term follow-up study
Source: Eur Respir J 2004; 24: Suppl. 48, 721s
Year: 2004

Factors related to response to intermittent treatment of mycobacterium avium complex lung disease
Source: Eur Respir J 2006; 28: Suppl. 50, 557s
Year: 2006

A double blind randomized study of aminoglycoside infusion with combined therapy for pulmonary mycobacterium avium complex disease
Source: Annual Congress 2006 - Clinical epidemiology of tuberculosis
Year: 2006


Combined chemotherapy in Mycobacterium avium complex pulmonary disease
Source: Eur Respir J 2005; 26: Suppl. 49, 657s
Year: 2005

The efficiency of including the II-line drugs to the treatment regimen of isoniazid-resistant tuberculosis.
Source: International Congress 2017 – MDRTB: detection and management
Year: 2017

Higher adverse drug reactions but better completion rate of twelve-dose weekly rifapentine plus isoniazid comparing with nine-month daily isoniazid for latent tuberculosis infection among patients under maintenance dialysis
Source: Virtual Congress 2020 – Tuberculosis: part 1
Year: 2020




The impact of different antibiotic treatment regimens on mortality in Mycobacterium avium complex pulmonary disease: a population-based cohort study
Source: Eur Respir J, 56 (3) 1901875; 10.1183/13993003.01875-2019
Year: 2020



Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment
Source: Eur Respir J 2003; 21: 478-482
Year: 2003



Is delamanid a potential agent in the treatment of diseases caused by Mycobacterium avium-intracellulare?
Source: Eur Respir J 2016; 48: 1803-1804
Year: 2016


Comparison of treatment of TB lymphadenitis with daily vs. intermittent chemotherapy
Source: Annual Congress 2011 - Pulmonary and extrapulmonary tuberculosis
Year: 2011